Vorasidenib Clinical Trials (2026): 18 Studies for Glioma & Low Grade Glioma of Brain
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
18 Vorasidenib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 15 indications (including Glioma & Low Grade Glioma of Brain) and 1,899 total planned enrollment. 4 Phase 3 Vorasidenib trials and 1 Phase 2 are listed. 9 Vorasidenib clinical trials are actively recruiting at 86 U.S. sites across 19 states. Most recent activity: NCT07215910 (Jan 2040).
Where to Participate: All Vorasidenib Trial Sites in the U.S. (86 sites across 19 states)
Every actively recruiting Vorasidenibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Arizona Clinical Trials | Chandler85225 | NCT07250633 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT07215910 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT07215910 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT07215910 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT07215910 | Map |
| CT | Yale University | New Haven06520 | NCT07215910 | Map |
| CT | Smilow Cancer Hospital Care Center-Trumbull | Trumbull06611 | NCT07215910 | Map |
| CT | Smilow Cancer Hospital Care Center - Waterford | Waterford06385 | NCT07215910 | Map |
| DE | Helen F Graham Cancer Center | Newark19713 | NCT07215910 | Map |
| DE | Medical Oncology Hematology Consultants PA | Newark19713 | NCT07215910 | Map |
| FL | Orlando Clinical Research Center | Orlando32809 | NCT07250633 | Map |
| IL | Illinois CancerCare-Bloomington | Bloomington61704 | NCT07215910 | Map |
| IL | OSF Saint Joseph Medical Center | Bloomington61701 | NCT07215910 | Map |
| IL | Illinois CancerCare-Canton | Canton61520 | NCT07215910 | Map |
| IL | Illinois CancerCare-Carthage | Carthage62321 | NCT07215910 | Map |
| IL | University of Illinois | Chicago60612 | NCT07215910 | Map |
| IL | Illinois CancerCare-Eureka | Eureka61530 | NCT07215910 | Map |
| IL | NorthShore University HealthSystem-Evanston Hospital | Evanston60201 | NCT07215910 | Map |
| IL | Illinois CancerCare-Galesburg | Galesburg61401 | NCT07215910 | Map |
| IL | NorthShore University HealthSystem-Glenbrook Hospital | Glenview60026 | NCT07215910 | Map |
| IL | NorthShore University HealthSystem-Highland Park Hospital | Highland Park60035 | NCT07215910 | Map |
| IL | Illinois CancerCare-Kewanee Clinic | Kewanee61443 | NCT07215910 | Map |
| IL | Illinois CancerCare-Macomb | Macomb61455 | NCT07215910 | Map |
| IL | Illinois CancerCare-Ottawa Clinic | Ottawa61350 | NCT07215910 | Map |
| IL | Illinois CancerCare-Pekin | Pekin61554 | NCT07215910 | Map |
| IL | Illinois CancerCare-Peoria | Peoria61615 | NCT07215910 | Map |
| IL | OSF Saint Francis Medical Center | Peoria61637 | NCT07215910 | Map |
| IL | OSF Saint Francis Radiation Oncology at Peoria Cancer Center | Peoria61615 | NCT07215910 | Map |
| IL | Illinois CancerCare-Peru | Peru61354 | NCT07215910 | Map |
| IL | Illinois CancerCare-Princeton | Princeton61356 | NCT07215910 | Map |
| IL | Illinois CancerCare - Washington | Washington61571 | NCT07215910 | Map |
| IL | Midwestern Regional Medical Center | Zion60099 | NCT07215910 | Map |
| IA | UI Health Care Mission Cancer and Blood - Ankeny Clinic | Ankeny50023 | NCT07215910 | Map |
| IA | UI Health Care Mission Cancer and Blood - West Des Moines Clinic | Clive50325 | NCT07215910 | Map |
| IA | Broadlawns Medical Center | Des Moines50314 | NCT07215910 | Map |
| IA | Iowa Methodist Medical Center | Des Moines50309 | NCT07215910 | Map |
| IA | Mercy Medical Center - Des Moines | Des Moines50314 | NCT07215910 | Map |
| IA | UI Health Care Mission Cancer and Blood - Des Moines Clinic | Des Moines50309 | NCT07215910 | Map |
| IA | UI Health Care Mission Cancer and Blood - Laurel Clinic | Des Moines50314 | NCT07215910 | Map |
| IA | UI Healthcare Mission Cancer and Blood - Pella | Pella50219 | NCT07215910 | Map |
| IA | UI Health Care Mission Cancer and Blood - Waukee Clinic | Waukee50263 | NCT07215910 | Map |
| LA | West Jefferson Medical Center | Marrero70072 | NCT07215910 | Map |
| LA | East Jefferson General Hospital | Metairie70006 | NCT07215910 | Map |
| LA | Children's Hospital New Orleans | New Orleans70118 | NCT07215910 | Map |
| LA | University Medical Center New Orleans | New Orleans70112 | NCT07215910 | Map |
| ME | MaineHealth Coastal Cancer Treatment Center | Bath04530 | NCT07215910 | Map |
| ME | MaineHealth Maine Medical Center - Portland | Portland04102 | NCT07215910 | Map |
| ME | MaineHealth Cancer Care Center of York County | Sanford04073 | NCT07215910 | Map |
| ME | MaineHealth Maine Medical Center- Scarborough | Scarborough04074 | NCT07215910 | Map |
| MI | University of Michigan Rogel Cancer Center | Ann Arbor48109 | NCT07215910 | Map |
| MI | University of Michigan - Brighton Center for Specialty Care | Brighton48116 | NCT07215910 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge | Basking Ridge07920 | NCT07215910 | Map |
| NJ | Memorial Sloan Kettering Monmouth | Middletown07748 | NCT07215910 | Map |
| NJ | Memorial Sloan Kettering Bergen | Montvale07645 | NCT07215910 | Map |
| NY | Northwell Health Imbert Cancer Center | Bay Shore11706 | NCT07215910 | Map |
| NY | Memorial Sloan Kettering Commack | Commack11725 | NCT07215910 | Map |
| NY | Memorial Sloan Kettering Westchester | Harrison10604 | NCT07215910 | Map |
| NY | Northwell Health/Center for Advanced Medicine | Lake Success11042 | NCT07215910 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT07215910 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07215910 | Map |
| NY | Stony Brook University Medical Center | Stony Brook11794 | NCT07215910 | Map |
| NY | Memorial Sloan Kettering Nassau | Uniondale11553 | NCT07215910 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT05609994 | Map |
| OH | University of Cincinnati Cancer Center-UC Medical Center | Cincinnati45219 | NCT07215910 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT07215910 | Map |
| OH | University of Cincinnati Cancer Center-West Chester | West Chester45069 | NCT07215910 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT07215910 | Map |
| PA | Christiana Care Health System-Concord Health Center | Chadds Ford19317 | NCT07215910 | Map |
| PA | UPMC Hillman Cancer Center Erie | Erie16505 | NCT07215910 | Map |
| PA | Forbes Hospital | Monroeville15146 | NCT07215910 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT07215910 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT07215910 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT07215910 | Map |
| PA | UPMC-Shadyside Hospital | Pittsburgh15232 | NCT07215910 | Map |
| PA | Wexford Health and Wellness Pavilion | Wexford15090 | NCT07215910 | Map |
| TX | American Research Corporation | San Antonio78215 | NCT07250633 | Map |
| VT | University of Vermont and State Agricultural College | Burlington05405 | NCT07215910 | Map |
| VT | University of Vermont Medical Center | Burlington05401 | NCT07215910 | Map |
| WI | Froedtert Menomonee Falls Hospital | Menomonee Falls53051 | NCT07215910 | Map |
| WI | Medical College of Wisconsin | Milwaukee53226 | NCT07215910 | Map |
| WI | ProHealth D N Greenwald Center | Mukwonago53149 | NCT07215910 | Map |
| WI | Froedtert and MCW Moorland Reserve Health Center | New Berlin53151 | NCT07215910 | Map |
| WI | Drexel Town Square Health Center | Oak Creek53154 | NCT07215910 | Map |
| WI | ProHealth Oconomowoc Memorial Hospital | Oconomowoc53066 | NCT07215910 | Map |
| WI | UW Cancer Center at ProHealth Care | Waukesha53188 | NCT07215910 | Map |
| WI | Froedtert West Bend Hospital/Kraemer Cancer Center | West Bend53095 | NCT07215910 | Map |
Vorasidenib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | approved for marketing | Total |
|---|---|---|---|---|---|---|
| P1 | 2 | 1 | 4 | 7 | ||
| P1/P2 | 1 | 1 | ||||
| P2 | 1 | 1 | ||||
| P3 | 2 | 2 | 4 | |||
| N/A | 2 | 2 | 1 | 5 |
Recruiting Vorasidenib clinical trials (9)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | P3 | Astrocytoma, IDH-Mutant, Grade 3 | 408 | Jul 2026 |
| NCT06809322 | VIGORVorasidenib Maintenance for IDH Mutant Astrocytoma | P3 | IDH-mutant Grade 2 or 3 Astrocytoma | 468 | Jan 2026 |
| NCT07286292 | Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | P2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | 10 | Mar 2026 |
| NCT07240662 | VIOLETAVorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma | — | Glioma | 150 | Dec 2025 |
| NCT05609994 | ViCToRyViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | P1 | Low Grade Glioma of Brain | 48 | Jul 2025 |
| NCT07469735 | VANGUARDVorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma | N/A | Glioma | 10 | Apr 2026 |
| NCT07547163 | LGG PRO'sPatient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared | — | Glioma | 90 | Apr 2025 |
| NCT06969352 | VICTORIAA Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study) | — | Gliomas | 60 | Jun 2025 |
| NCT07250633 | Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants | P1 | Severe Hepatic Impairment | 20 | Apr 2026 |
Vorasidenib clinical trials by indication
Glioma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07240662 | VIOLETA | N/A | recruiting | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma |
| NCT07469735 | VANGUARD | N/A | not yet recruiting | Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma |
| NCT07547163 | LGG PRO's | N/A | recruiting | Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared |
| NCT05592743 | — | N/A | approved for marketing | Vorasidenib Expanded Access Program |
Severe Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07250633 | — | P1 | recruiting | Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants |
Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07286292 | — | P2 | not yet recruiting | Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation |
IDH-mutant Grade 2 or 3 Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06809322 | VIGOR | P3 | recruiting | Vorasidenib Maintenance for IDH Mutant Astrocytoma |
Healthy Adult Female Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07235774 | — | P1 | completed | A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants |
Astrocytoma, IDH-Mutant, Grade 3 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07215910 | — | P3 | recruiting | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer |
Healthy Adult Participants (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07235748 | — | P1 | completed | Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants |
Low Grade Glioma of Brain (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05609994 | ViCToRy | P1 | recruiting | ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas |
Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06969352 | VICTORIA | N/A | not yet recruiting | A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study) |
IDH1-mutant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06478212 | TMZ | P1/P2 | active not recruiting | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma |
Residual or Recurrent Grade 2 IDH Mutant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06780930 | — | P3 | active not recruiting | Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation |
Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05843708 | — | P1 | completed | A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects |
Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05674474 | — | P1 | completed | A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function |
Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05484622 | — | P1 | active not recruiting | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma |
Grade 2 Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04164901 | AG-881 | P3 | active not recruiting | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) |
Vorasidenib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VIGOR | NCT06809322 | P3 | recruiting | IDH-mutant Grade 2 or 3 Astrocytoma | 468 | — |
| AG-881 | NCT04164901 | P3 | active not recruiting | Grade 2 Glioma | 331 | PMID 37272516 |
All Vorasidenib trials (18)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07215910 | Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer | P3 | recruiting | 408 | Alliance for Clinical Trials in Oncology | Jul 2026 | |
| NCT06809322 | VIGOR | Vorasidenib Maintenance for IDH Mutant Astrocytoma | P3 | recruiting | 468 | European Organisation for Research and Treatment of Cancer - EORTC | Jan 2026 |
| NCT07286292 | Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | P2 | not yet recruiting | 10 | Institut de Recherches Internationales Servier (I.R.I.S.) | Mar 2026 | |
| NCT07240662 | VIOLETA | Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse Glioma | — | recruiting | 150 | iOMEDICO AG | Dec 2025 |
| NCT06780930 | Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation | P3 | active not recruiting | 57 | Servier | Oct 2024 | |
| NCT05609994 | ViCToRy | ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas | P1 | recruiting | 48 | Katy Peters, MD, PhD | Jul 2025 |
| NCT06478212 | TMZ | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | P1/P2 | active not recruiting | 51 | Institut de Recherches Internationales Servier | Jan 2025 |
| NCT04164901 | AG-881 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | P3 | active not recruiting | 331 | Institut de Recherches Internationales Servier | Jan 2020 |
| NCT07469735 | VANGUARD | Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma | N/A | not yet recruiting | 10 | Huashan Hospital | Apr 2026 |
| NCT07547163 | LGG PRO's | Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared | — | recruiting | 90 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Apr 2025 |
| NCT05484622 | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | P1 | active not recruiting | 60 | Institut de Recherches Internationales Servier | Jan 2023 | |
| NCT06969352 | VICTORIA | A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study) | — | not yet recruiting | 60 | Servier (Tianjin) Pharmaceutical Co. LTD. | Jun 2025 |
| NCT07250633 | Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants | P1 | recruiting | 20 | Institut de Recherches Internationales Servier (I.R.I.S.) | Apr 2026 | |
| NCT07235774 | A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants | P1 | completed | 28 | Institut de Recherches Internationales Servier (I.R.I.S.) | Nov 2025 | |
| NCT07235748 | Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants | P1 | completed | 28 | Institut de Recherches Internationales Servier (I.R.I.S.) | Oct 2025 | |
| NCT05843708 | A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects | P1 | completed | 64 | Servier Bio-Innovation LLC | Apr 2023 | |
| NCT05674474 | A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function | P1 | completed | 16 | Institut de Recherches Internationales Servier | Mar 2023 | |
| NCT05592743 | Vorasidenib Expanded Access Program | — | approved for marketing | 0 | Servier | — |
Vorasidenib clinical trials: frequently asked questions
- How many Vorasidenib clinical trials are there?
- 18 Vorasidenib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 4 are marked completed.
- Are Vorasidenib clinical trials recruiting in 2026?
- Yes — 6 Vorasidenib trials are actively recruiting in 2026, with 86 U.S. sites across 19 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Vorasidenib being studied for?
- Vorasidenib is being studied for Glioma, Low Grade Glioma of Brain, Diffuse Glioma, Disease Attributes, Glioma of Brain and 30 more. The trials are grouped by indication on this page.
- What phase is Vorasidenib in?
- Vorasidenib clinical trials span 4 Phase 3, 1 Phase 2, 7 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Vorasidenib clinical trials?
- The lead sponsor across the most Vorasidenib trials is Institut de Recherches Internationales Servier, with 10 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Vorasidenibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: